Research Confirms Effectiveness Of Cognigram; New Test For Alzheimer’s Disease

  Research Confirms Effectiveness Of Cognigram; New Test For Alzheimer’s
  Disease

Business Wire

MELBOURNE, Australia -- January 14, 2014

For patients over the age of 50, a routine physical exam at the doctor’s
office typically covers a wide spectrum of medical biomarkers with one glaring
exception, cognitive health. Unless there have been unusual mental changes or
challenges in their daily life, tests of a patient’s attention, memory or
brain processing speed is usually not part of a check-up.

To detect the early, subtle signs of mild cognitive impairment (MCI) which may
lead to forms of dementia, including Alzheimer’s disease, there is a need for
a standardized test that can alert physicians to a possible cognitive decline.
Last week, research from the Florey Institute of Neuroscience and Mental
Health in Australia reported that a brief, online set of cognitive tests,
commercially known as Cognigram, can detect early signs of MCI and
Alzheimer’s.

Cognigram has been developed by Cogstate, a leading medical technology company
specialising in cognitive assessment and training. Cognigram is available to
primary care physicians to provide a dementia test at the point of care in
Canada through an exclusive agreement with Merck Canada. More than 580 primary
care physicians have registered to use Cognigram and 20 testing centres are
now live.

To evaluate the functional health of a human brain, physicians need to observe
performance on several key domains. To assess the state of sub cortical brain
regions including the basal ganglia as well as cortical regions such as the
prefrontal and parietal cortices, tests of attention and reaction time are
used. Learning and working memory depend on normal functioning of the
hippocampus and temporal lobe (for pattern separation) and prefrontal cortex
and anterior cingulate (for working memory).

By grouping these two domains, attention/reaction and learning/memory, into
composite scores, the research team, led by Paul Maruff PhD, Chief Science
Officer of Cogstate, was able to compare test results with traditional
hallmarks of MCI and AD.

“The presence of a relatively greater impairment in cognitive functions
dependent on cortical and limbic brain regions (i.e., learning and working
memory) with relatively subtle impairment in motor and attention functions is
consistent with neuropsychological models of AD which emphasize that cognitive
impairment characteristic of both prodromal and clinically classified AD is
disruption to memory and executive function,” said Dr Maruff.

To test this, they recruited volunteers from the Australian Imaging,
Biomarkers and Lifestyle (AIBL) Study, dividing them into three groups; 653
healthy adults, 107 with amnesic MCI (where the primary symptom is memory
loss), and 44 with AD. They were all asked to complete the four tests of the
Cogstate brief battery, also known as Cognigram, and the speed and accuracy of
the results were recorded.

All of the Cogstate tests use a deck of playing cards as their focus point. No
knowledge of any card games is required, patients simply answer a yes/no
question about what and when cards are shown to them. For the
attention/reaction composite, volunteers completed the Detection task,
pressing a certain key on a computer keyboard as soon as a card is turned
over, as well as the Identification task, answering yes or no if a card turned
over is the color red.

For the learning/working memory composite, two additional tests were used. The
One Card Learning task asks, “Have you seen this card before in this task?” To
test immediate recall, the One Back test asks if the card displayed is the
same as the immediately prior card.

As hypothesized by the research team, the results showed that both the MCI and
the AD groups performed significantly worse on both composites than the
healthy adults. Also, the AD group’s learning/memory score was significantly
lower than the MCI group, demonstrating the presence and progression of the
memory decline caused by the disease.

To be a reliable diagnostic tool for physicians, the test battery needs to be
able to show consistent results over time. The Cognigram testing was repeated
four times in three months and showed statistically similar results across all
groups.

The full study can be accessed online at BMC Psychology.

“We are excited about the results of this study,” said Maruff. “The Cogstate
brief battery has been found to be sensitive to amyloid related cognitive
change in many trials. This study shows for the first time, that a version of
the test designed specifically for clinical practice; the Cognigram battery,
has excellent sensitivity and specificity to mild cognitive impairment.”

Contact:

Cogstate
Media (US):
Dan Peterson, +1-203-773-5010
danpeterson@cogstate.com
or
Media (Australia):
Ben Oliver, +61 3 9866 4722
boliver@buchanwe.com.au
 
Press spacebar to pause and continue. Press esc to stop.